Cirrhosis is an important cause of morbidity and mortality in people with chronic liver
disease worldwide. In 2019, cirrhosis was associated with 2.4% of global deaths. Owing to …

Over the last two decades, there have been tremendous advances in the non-invasive
diagnosis and risk stratification of chronic liver diseases (CLDs). Non-invasive approaches …

Background Immunotherapy with immune checkpoint inhibitors combined with an anti-
angiogenic tyrosine-kinase inhibitor (TKI) has been shown to improve overall survival versus …

Importance Hepatitis C virus (HCV) is the most common chronic blood-borne pathogen in
the US and a leading cause of complications from chronic liver disease. HCV is associated …

HCV eradication by antiviral treatment reduces but does not eliminate HCC risk. Patients
with established cirrhosis require HCC surveillance “indefinitely” after sustained virologic …

Objective The benefit of direct-acting antivirals (DAAs) against HCV following successful
treatment of hepatocellular carcinoma (HCC) remains controversial. This meta-analysis of …

Background and Aims HCV cure reduces but does not eliminate the risk of HCC. HCC
surveillance is recommended in populations where the incidence exceeds 1.5% per year. In …

Abstract The Infectious Diseases Society of America and the American Association for the
Study of Liver Diseases have collaboratively developed evidence-based guidance …

This first Practice Guidance on Reproductive Health from the American Association for the
Study of Liver Diseases (AASLD) is intended to be a comprehensive reference on …

The Consolidated guidelines on HIV, viral hepatitis and STI prevention, diagnosis, treatment
and care for key populations outline a public health response for five key populations (men …